|
|
Volumn 347, Issue 6223, 2015, Pages 701-702
|
|
Ebola drug trials lurch ahead
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
FAVIPIRAVIR;
AMIDE;
BRINCIDOFOVIR;
CYTOSINE;
MONOCLONAL ANTIBODY;
PHOSPHONIC ACID DERIVATIVE;
PYRAZINE DERIVATIVE;
ZMAPP;
ADENOVIRUS INFECTION;
CYTOMEGALOVIRUS INFECTION;
DRUG EFFICACY;
DRUG RESEARCH;
DRUG SCREENING;
EBOLA HEMORRHAGIC FEVER;
EPIDEMIC;
GOVERNMENT;
GUINEA;
HEALTH CARE AVAILABILITY;
HUMAN;
LIBERIA;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SIERRA LEONE;
STUDY DESIGN;
ANALOGS AND DERIVATIVES;
CLINICAL TRIAL (TOPIC);
DISEASE OUTBREAKS;
EBOLA VIRUS;
HEMORRHAGIC FEVER, EBOLA;
MORTALITY;
TRENDS;
AMIDES;
ANTIBODIES, MONOCLONAL;
ANTIVIRAL AGENTS;
CLINICAL TRIALS AS TOPIC;
CYTOSINE;
DISEASE OUTBREAKS;
EBOLAVIRUS;
HEMORRHAGIC FEVER, EBOLA;
HUMANS;
ORGANOPHOSPHONATES;
PYRAZINES;
|
|
EID: 84923108405
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.347.6223.701 Document Type: Note |
|
Times cited : (19)
|
|
References (0)
|